Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ANAB 
AnaptysBio Inc (ANAB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/11/2025: ANAB (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -7.05% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 564.27M USD | Price to earnings Ratio - | 1Y Target Price 37.64 |
Price to earnings Ratio - | 1Y Target Price 37.64 | ||
Volume (30-day avg) 1184048 | Beta 0.03 | 52 Weeks Range 12.21 - 41.31 | Updated Date 04/2/2025 |
52 Weeks Range 12.21 - 41.31 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.12 |
Earnings Date
Report Date 2025-03-10 | When Before Market | Estimate -1.7049 | Actual -0.72 |
Profitability
Profit Margin -159.1% | Operating Margin (TTM) -22.43% |
Management Effectiveness
Return on Assets (TTM) -15.35% | Return on Equity (TTM) -182.71% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 200452790 | Price to Sales(TTM) 6.18 |
Enterprise Value 200452790 | Price to Sales(TTM) 6.18 | ||
Enterprise Value to Revenue 2.2 | Enterprise Value to EBITDA -1.3 | Shares Outstanding 30666800 | Shares Floating 18032374 |
Shares Outstanding 30666800 | Shares Floating 18032374 | ||
Percent Insiders 4.41 | Percent Institutions 121.92 |
Analyst Ratings
Rating 4.27 | Target Price 35.7 | Buy 2 | Strong Buy 6 |
Buy 2 | Strong Buy 6 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
AnaptysBio Inc
Company Overview
History and Background
AnaptysBio, Inc. is a biotechnology company founded in 2005. It focuses on developing antibody therapies for inflammatory diseases. Originally focused on antibody discovery, it has transitioned to clinical development and partnerships.
Core Business Areas
- Inflammation & Immuno-Oncology: Development of antibody therapies targeting inflammatory and immuno-oncology diseases through partnership and internal research.
Leadership and Structure
The company is led by Hamza Suria (CEO). It has a board of directors and a management team overseeing research, development, and operations.
Top Products and Market Share
Key Offerings
- Roxadustat (partnered with GSK outside the US): AnaptysBio retains royalties related to sales of Roxadustat by GSK, which treats anemia associated with chronic kidney disease. Competitors include erythropoiesis-stimulating agents (ESAs) and other anemia treatments. Royalty revenue varies based on GSK sales, but AnaptysBio does not directly market Roxadustat. The worldwide market for anemia drugs is valued at over $10 billion, with ESA's having the largest share, and Roxadustat's current share still relatively small.
- Imsidolimab: A fully human anti-IL-36R antibody. It is currently being evaluated for the treatment of generalized pustular psoriasis (GPP). Competing GPP treatments and therapeutics in development are from companies like Boehringer Ingelheim, and UCB. No specific market share for Imsidolimab currently as it is still in clinical trials and not yet commercialized.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with companies developing new therapies for a wide range of diseases. Innovation, regulatory hurdles, and market access are key drivers.
Positioning
AnaptysBio is positioned as a clinical-stage biotechnology company focused on antibody therapeutics. Its competitive advantages include its antibody discovery platform and partnerships with larger pharmaceutical companies.
Total Addressable Market (TAM)
The total addressable market for AnaptysBio depends on the success of its drug candidates in specific indications. The combined TAM for inflammatory diseases and immuno-oncology is substantial, potentially exceeding $100 billion. AnaptysBio's TAM is dependent on their partnered products as well as products currently in clinical trials.
Upturn SWOT Analysis
Strengths
- Proprietary antibody discovery platform
- Strategic partnerships with major pharmaceutical companies
- Strong cash position (relative to its size)
- Focus on innovative therapies for inflammatory diseases
- Clinical stage assets with demonstrated efficacy
Weaknesses
- Reliance on partnered programs for revenue
- High R&D expenses
- Clinical trial risk
- Limited commercial infrastructure (currently partner dependent)
- Dependence on clinical trial results of compounds currently in development
Opportunities
- Advancement of internal pipeline programs
- Expansion of existing partnerships
- New strategic collaborations
- Potential for regulatory approvals of lead candidates
- Development of new antibody therapies
Threats
- Clinical trial failures
- Competition from other biotechnology companies
- Regulatory hurdles
- Patent challenges
- Economic downturn impacting R&D spending
Competitors and Market Share
Key Competitors
- LLY
- ABBV
- BMY
Competitive Landscape
AnaptysBio is substantially smaller than major pharmaceutical companies like LLY, ABBV, and BMY. AnaptysBio relies on innovation and partnerships to compete, whereas the other players derive revenue from already approved therapies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth has been primarily driven by milestone payments and royalties from partnered programs.
Future Projections: Future growth depends on the success of Imsidolimab and partnered assets, with analyst estimates varying widely due to the inherent uncertainty in biotech drug development.
Recent Initiatives: Focus on Imsidolimab development, potential partnerships for new indications, and continued royalty stream from Roxadustat.
Summary
AnaptysBio is a clinical-stage biotechnology company with potential in its lead asset, Imsidolimab, and royalty revenue. They have good strategic partnerships. Their success is heavily reliant on successful clinical trial outcomes. AnaptysBio's small size and dependence on partnered revenue streams represent risks to investors.
Similar Companies
ABBV
AbbVie Inc
ABBV
AbbVie Inc
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
GSK
GlaxoSmithKline PLC ADR
GSK
GlaxoSmithKline PLC ADR
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AnaptysBio Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2017-01-26 | President, CEO & Director Mr. Daniel R. Faga | ||
Sector Healthcare | Industry Biotechnology | Full time employees 136 | Website https://www.anaptysbio.com |
Full time employees 136 | Website https://www.anaptysbio.com | ||
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.